

Almirall at a glance

Who we are

We are a global pharmaceutical company dedicated to medical dermatology. As a family-owned business, we think in generations and apply this long-term view to our contributions to people with skin conditions, dermatology, and society. Our passion for medical dermatology and our collaborative mindset enable us to develop and deliver innovative and impactful treatments for people with skin diseases to transform our patients' world by helping them to realize their hopes and dreams for a healthy life. Our purpose places patients at the center of our business ambition and is an inspiration for our employees that work every day with the knowledge of their impact on people.

Headquartered in	Offices around the world	Total employees	Country presence
Barcelona	15	1,904	102

Patients at the core

Number of products	Dermatology products	Patients we have helped with our key dermatology products ¹
143	51	628,181

¹ The total number includes Klisyri® (tirbanibulin), Ilumetri® (tildrakizumab), Wynzora® (calcipotriol/betamethasone) and Seysara (sarecycline) in 2023.

Key dermatology products

Psoriasis: Ilumetri® (tildrakizumab), Wynzora® (CAL/BDP), Skilarence® (dimethyl fumarate)

Atopic Dermatitis: EBGLYSS® (lebrikizumab), Cordran® Tape (flurandrenolide), Decoderm (Fluprednidene)

Actinic Keratosis: Klisyri® (tirbanibulin), Actikerall® (fluorouracil/salicylic acid), Solaraze® (diclofenac sodium)

Acne: Seysara® (sarecycline); Aczone®

Onychomycosis: Ciclopoli® nail lacquer franchise (ciclopirox)

Other products

Sativex® franchise (THC:CBD), Crestor® / Provisacor® (rosuvastatin), Almax® (almagate), Ebastel® franchise (ebastine),

Efficib® (sitagliptin/metformin) / Tesavel® (sitagliptin), Prometax® (rivastigmine patches), Physiorelax® franchise (Helenalin2)

What we do

With an R&D pipeline solely focused on medical dermatology and a strong dermatology and non-dermatology portfolio, we are at the forefront of science to develop and deliver ground-breaking, differentiated end-to-end products that address patients' needs. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose of improving patients' lives holistically.

Key figures in 2023



Driven by innovation

Investment of Net Sales in R&D	Current projects in the pipeline	Current collaborations and partnerships in R&D
12.4%	15	23

New collaborations recently signed:

Barcelona Supercomputing Center and Nostrum Biodiscovery – ARTIBAND Generative artificial intelligence (AI)	Absci generative AI	EpimAb bispecific antibodies
CRG Non-melanoma skin cancer and atopic dermatitis	etherna mRNA-based therapies for serious skin conditions	Eloxx pharmaceuticals Rare diseases
		Novo Nordisk Autoimmune dermatology diseases

We focus on three core therapeutic areas:

Immune inflammatory diseases	Non-melanoma skin cancer	Rare diseases
Atopic dermatitis Psoriasis Alopecia areata Vitiligo Hidradenitis suppurativa	Actinic keratosis Basal cell carcinoma Cutaneous T-cell lymphoma Squamous cell carcinoma	Autoimmune bullous diseases Epidermolysis bullosa Palmoplantar pustulosis

Pipeline

Pre-clinical	Phase I	Phase III	Under registration
ALM412 Rare dermatological diseases	ALM401 Autoimmune dermatology	Tirbanibulin Actinic keratosis	Sarecycline Acne
	ALM27134 Autoimmune dermatology		Efinaconazole Onychomycosis
	ALM223 Autoimmune dermatology		